GSK

News

GSK pushes 'next-generation' mRNA flu shot into phase 3

Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.

News

Trodelvy gets EU nod for first-line triple-neg breast cancer

A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.

News

Japan first approval for GSK’s bepirovirsen for CHB

Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients

News

GSK to quit Stevenage for new R&D site in Cambridge

In a major shake-up of its UK operations, GSK is building a brand new R&D centre in Cambridge and transfer operations there from its Stevenage campus.

News

J&J's oral IL-23 drug backed for psoriasis in EU

J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

GSK pushes 'next-generation' mRNA flu shot into phase 3

Trodelvy gets EU nod for first-line triple-neg breast cancer

Japan first approval for GSK’s bepirovirsen for CHB

GSK to quit Stevenage for new R&D site in Cambridge

J&J's oral IL-23 drug backed for psoriasis in EU

Nuvalent buy delivers new cancer approval for GSK

US puts $125m into personalised RNA therapy production

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks